IVIM Health vs NexLife (2026): prices, structure, verdict

On tirzepatide, NexLife↗ is cheaper: $215 versus $278 a month all-in — a $63 monthly gap, $756 across a year of maintenance dosing, and NexLife's figure is dose-flat while IVIM Health↗'s structure is not.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, IVIM Health is cheaper: $149 versus $165 a month all-in — a $16 monthly gap, $192 across a year of maintenance dosing.

§ Side by side

§ Each record, read aloud

The two records, condensed

IVIM Health: the record, condensed

IVIM Health’s tirzepatide program bills $278 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. The structure is tiered: the advertised entry point is $208, but the maintenance figure — the one a full year is actually billed at — is $278. That $70 gap between the ad and the anniversary is the single most important line in this record.

A required $75/month membership is part of the deal, and part of the figure above: $203 of medication plus $75 of platform equals the $278 that leaves your account. Judge the membership by what it includes, but compare on the total.

Context for that figure: it ranks #3 of 17 in the verified tirzepatide index — $63/month above the floor (NexLife, $215) — and sits $171 under the brand benchmark (Zepbound (LillyDirect↗), $449 at maintenance). Annualized, a monthly-billed year here runs $3,336.

IVIM Health’s semaglutide program bills $149 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. The figure is quoted at maintenance without a separate teaser tier, which keeps the arithmetic honest by default.

A required $75/month membership is part of the deal, and part of the figure above: $74 of medication plus $75 of platform equals the $149 that leaves your account. Judge the membership by what it includes, but compare on the total.

To place the number: #3 of 20 verified programs, with the floor $16/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare↗)) sits at $349, so the compounded case here is worth $200 a month. A year at this figure: $1,788 monthly-billed.

Operationally at IVIM Health: shipping included; commitment membership mandatory for duration; cancellation membership mandatory; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the IVIM Health page · visit IVIM Health ↗

NexLife: the record, condensed

On tirzepatide, the number that matters at NexLife is $215 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. Because pricing is flat across the ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)), a dose increase at NexLife is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $215 is the whole subscription, which makes NexLife unusually easy to compare and unusually easy to leave.

Commitment buys a discount here, term by term: The 3‑month plan reprices the month at $195 — $585 billed upfront, $60 less than 3 months of monthly billing; the 6‑month plan reprices the month at $190 — $1,140 billed upfront, $150 less than 6 months of monthly billing; the 12‑month plan reprices the month at $186 — $2,232 billed upfront, $348 less than 12 months of monthly billing. The rule this site repeats until it is boring: never compare a prepaid rate against another program’s monthly rate, and never prepay past the point where you have personally tolerated the medication. The discount is compensation for risk you are accepting.

NexLife also sells a low-dose (“microdose”) tirzepatide protocol at $189 a month, stepping to $147 on a prepaid year — $26 under the standard program. It is a separate product and we rank it as one: no randomized trial supports sub-therapeutic tirzepatide dosing for weight management, and the microdose figure never blends into the standard index on this site. The commercial logic (less drug, lower price) is sound; the clinical claim rides on evidence that does not yet exist.

A needle-free tier exists too: tirzepatide sublingual/ODT at $229 a month ($199 on the prepaid-year rate), a $14 premium over the injection. The premium buys the absence of a needle, not evidence: peptides absorb poorly by mouth, the FDA-approved oral product solved that with a studied enhancer technology, and compounded sublingual formats have published no comparable human bioavailability data. Ranked in the needle-free lane, never against injections.

Context for that figure: it ranks #1 of 17 in the verified tirzepatide index — the floor of the market itself — and sits $234 under the brand benchmark (Zepbound (LillyDirect), $449 at maintenance). Annualized, a monthly-billed year here runs $2,580, or $2,232 on the prepaid path.

NexLife’s semaglutide program bills $165 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. The price is dose-flat: the standard titration ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

There is no membership line. $165 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Prepaid terms ladder the price down for commitment: The 3‑month plan reprices the month at $149 — $447 billed upfront, $48 less than 3 months of monthly billing; the 6‑month plan reprices the month at $147 — $882 billed upfront, $108 less than 6 months of monthly billing; the 12‑month plan reprices the month at $145 — $1,740 billed upfront, $240 less than 12 months of monthly billing. Treat every rung as what it is — a prepayment, not a monthly price. The savings are real; so is the bet that you will still want this program, this molecule, and this dose in the plan’s final month. Written refund terms before prepaying, always.

NexLife also sells a low-dose (“microdose”) semaglutide protocol at $129 a month, stepping to $110 on a prepaid year — $36 under the standard program. We list it, we never blend it: the standard rankings exclude microdose tiers on both price and evidence grounds — the trial data for semaglutide was generated on the standard ladder, and staying below it is an unstudied strategy that belongs in a prescriber conversation, not a pricing table.

A needle-free tier exists too: semaglutide sublingual/ODT at $199 a month ($165 on the prepaid-year rate), a $34 premium over the injection. Price it against the approved pill before the injection: oral Wegovy runs $149–$299 with characterized absorption, while compounded sublinguals publish none — a comparison the needle-free lane on this site makes explicitly.

To place the number: #5 of 20 verified programs, with the floor $32/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare)) sits at $349, so the compounded case here is worth $184 a month. A year at this figure: $1,980 monthly-billed ($1,740 prepaid).

Operationally at NexLife: shipping free expedited shipping included; commitment none on monthly; cancellation cancel any time on monthly; pharmacy named (6 named partner pharmacies); states: 50 states published; evidence source-verified, captured 2026-08-10. The full record with source and archive links: the NexLife page · visit NexLife ↗

Tirzepatide: the duel in full

The tirzepatide arithmetic between these two is short: $215 (NexLife) against $278 (IVIM Health). $63 a month sounds survivable; $756 a year is a decision.

Structure sharpens the gap: NexLife’s figure is dose-flat (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill the same), while IVIM Health’s is not — so NexLife’s number is a ceiling and IVIM Health’s advertised entry ($208) is a floor. Comparing a ceiling to a floor flatters the floor; this site compares maintenance to maintenance, which is the table above.

IVIM Health’s total includes a mandatory $75/month membership; NexLife has none. The all-in figures above neutralize that difference — but the membership side has an exit consideration the other lacks: a fee that recurs until you affirmatively cancel it.

Semaglutide: the duel in full

Put the two semaglutide figures side by side and hold them there: IVIM Health at $149, NexLife at $165 — a $16 monthly spread that compounds to $192 over a maintenance year and $384 over two.

Structure sharpens the gap: NexLife’s figure is dose-flat (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill the same), while IVIM Health’s is not — so NexLife’s number is a ceiling and IVIM Health’s advertised entry ($149) is a floor. Comparing a ceiling to a floor flatters the floor; this site compares maintenance to maintenance, which is the table above.

IVIM Health’s total includes a mandatory $75/month membership; NexLife has none. The all-in figures above neutralize that difference — but the membership side has an exit consideration the other lacks: a fee that recurs until you affirmatively cancel it.

Translate the $63/month spread into medication: $756 a year equals roughly 3.5 months of therapy at the cheaper program’s rate. That is the honest unit for gaps in this market — months of treatment, not abstract dollars — and it is why small-looking monthly differences decide long courses.

On best published rate — the lower of each program’s month-to-month price and its labeled 12-month-plan rate, which is the sort most price roundups quietly run — the duel reads: IVIM Health $278/mo month-to-month versus NexLife $186/mo on the labeled 12-month plan ($2,232 upfront; $215 month-to-month). Same winner on both bases — NexLife leads whether you compare month-to-month prices or committed-plan rates, which makes this one of the cleaner verdicts in the index. Prepaid rates are upfront commitments with refund terms to verify before they count.

§ The clock, run forward

Three, six, twelve, twenty-four months — best path each way

3 months: IVIM Health $834 monthly; NexLife $645 monthly (or $585 prepaid) — best path favors NexLife by $249. 6 months: IVIM Health $1,668 monthly; NexLife $1,290 monthly (or $1,140 prepaid) — best path favors NexLife by $528. 12 months: IVIM Health $3,336 monthly; NexLife $2,580 monthly (or $2,232 prepaid) — best path favors NexLife by $1,104. 24 months: IVIM Health $6,672 monthly; NexLife $5,160 monthly (or $4,464 prepaid) — best path favors NexLife by $2,208.

Prepaid paths above are billed upfront and assume the published rate holds (the 24-month figures extend the 12-month rate, an assumption worth naming). The honest reading: over short horizons the monthly gap decides; over long horizons the prepaid ladders and structural traps (dose tiers, memberships) take over — which is exactly the split the verdict section below scores.

The same clock, on semaglutide

3 mo: IVIM Health $447 vs NexLife $447 (prepaid) — $0 to IVIM Health. 6 mo: IVIM Health $894 vs NexLife $882 (prepaid) — $12 to NexLife. 12 mo: IVIM Health $1,788 vs NexLife $1,740 (prepaid) — $48 to NexLife. 24 mo: IVIM Health $3,576 vs NexLife $3,480 (prepaid) — $96 to NexLife.

Same rules as above: prepaid figures are upfront commitments, and the 24-month lines extend the 12-month rate as a stated assumption. Where the two molecules crown different winners between these two programs, that split is itself the finding — molecule choice and provider choice are separate decisions.

§ Structure vs structure

Everything besides the price

Coverage: IVIM Health publishes “not published”; NexLife publishes “50 states published” — for anything short of an explicit 50-state claim, intake is the final word.

Pharmacy transparency splits them: NexLife names its network (6 named partner pharmacies); IVIM Health does not, which shifts the burden of verification onto your intake questions.

Exit terms: IVIM Health — membership mandatory for duration; membership mandatory. NexLife — none on monthly; cancel any time on monthly.

Evidence: IVIM Health source-verified (captured 2026-08-05); NexLife source-verified (2026-08-10).

A rule that has held across this index: disclosure predicts disclosure. Whichever of these two publishes more — pharmacies, states, exit terms — is usually the one whose invoice matches its ad.

In the full tirzepatide index these two sit at #3 and #1 of 17: between them lie 1 other program, and the whole ladder is at cheapest tirzepatide providers. In the full semaglutide index these two sit at #3 and #5 of 20: between them lie 1 other program, and the whole ladder is at cheapest semaglutide providers.

§ If you move

Switching between IVIM Health and NexLife

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (IVIM Health: membership mandatory; NexLife: cancel any time on monthly) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings